SEOUL/TOKYO (Reuters) -Toyota and Hyundai Motor may have a beef with U.S. protectionism, but they have one thing in common with President Donald Trump: when it comes to global car markets, it's ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R&D pipeline in the process.

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s current president, CEO and ...

Julie Kim, president of the company's U.S. unit, was named to succeed Weber in June 2026. Weber, one of the highest-profile foreign CEOs in Japan, spearheaded Takeda's $59 billion takeover of ...

“The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company's success under Christophe Weber's remarkable leadership,” said Masami ...

Business Wire India CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession pro ...

Takeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 202630.01.2025, 09:31 Uhr von EQS News Jetzt kommentieren: 0 ...

EQS-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word (s): Personnel Takeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 30-Jan-2025 / ...

Takeda Pharmaceutical raised its annual earnings forecasts despite posting lower quarterly net profit, and it said Julie Kim, who heads its U.S. business unit, will become chief executive in 2026 ...